ACRS vs. HRMY

Last updated Apr 1, 2026

Compare and contrast key facts about Aclaris Therapeutics, Inc. (ACRS) and Harmony Biosciences Holdings, Inc. (HRMY).

Performance

ACRS vs. HRMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aclaris Therapeutics, Inc. (ACRS) and Harmony Biosciences Holdings, Inc. (HRMY). The values are adjusted to include any dividend payments, if applicable.

ACRS vs. HRMY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ACRS Aclaris Therapeutics, Inc.	24.58%	21.37%	136.19%	-93.33%	8.32%	124.73%	161.94%
HRMY Harmony Biosciences Holdings, Inc.	-25.15%	8.75%	6.53%	-41.38%	29.22%	17.95%	-2.32%

Fundamentals

Market Cap ACRS : $459.99M HRMY : $1.64B
EPS ACRS : -$0.53 HRMY : $3.33
PS Ratio ACRS : 58.76 HRMY : 1.89
PB Ratio ACRS : 4.46 HRMY : 1.89
Total Revenue (TTM) ACRS : $7.83M HRMY : $868.45M
Gross Profit (TTM) ACRS : $5.74M HRMY : $670.11M
EBITDA (TTM) ACRS : -$71.59M HRMY : $238.25M

Returns By Period

In the year-to-date period, ACRS achieves a 24.58% return, which is significantly higher than HRMY's -25.15% return.

ACRS

• 1D: 7.45%
• 1M: 30.66%
• YTD: 24.58%
• 6M: 97.37%
• 1Y: 145.10%
• 3Y*: -22.61%
• 5Y*: -32.37%
• 10Y*: -15.62%

HRMY

• 1D: 4.13%
• 1M: -1.86%
• YTD: -25.15%
• 6M: 1.63%
• 1Y: -15.61%
• 3Y*: -4.98%
• 5Y*: -2.68%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ACRS vs. HRMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACRS

ACRS Risk / Return Rank: 87
ACRS Sharpe Ratio Rank: 83
ACRS Sortino Ratio Rank: 90
ACRS Omega Ratio Rank: 85
ACRS Calmar Ratio Rank: 89
ACRS Martin Ratio Rank: 87

HRMY

HRMY Risk / Return Rank: 25
HRMY Sharpe Ratio Rank: 25
HRMY Sortino Ratio Rank: 25
HRMY Omega Ratio Rank: 24
HRMY Calmar Ratio Rank: 28
HRMY Martin Ratio Rank: 25

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACRS vs. HRMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aclaris Therapeutics, Inc. (ACRS) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ACRS	HRMY	Difference
Sharpe ratio Return per unit of total volatility	1.48	-0.37	+1.85
Sortino ratio Return per unit of downside risk	2.86	-0.24	+3.10
Omega ratio Gain probability vs. loss probability	1.33	0.96	+0.37
Calmar ratio Return relative to maximum drawdown	3.71	-0.45	+4.16
Martin ratio Return relative to average drawdown	9.22	-0.98	+10.19
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ACRS vs. HRMY - Sharpe Ratio Comparison

The current ACRS Sharpe Ratio is 1.48, which is higher than the HRMY Sharpe Ratio of -0.37. The chart below compares the historical Sharpe Ratios of ACRS and HRMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ACRS	HRMY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.48	-0.37	+1.85
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.35	-0.05	-0.30
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.14	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	-0.09	0.00

Correlation

The correlation between ACRS and HRMY is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ACRS vs. HRMY - Dividend Comparison

Neither ACRS nor HRMY has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ACRS vs. HRMY - Drawdown Comparison

The maximum ACRS drawdown since its inception was -98.05%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for ACRS and HRMY.

Drawdown Indicators

	ACRS	HRMY	Difference
Max Drawdown Largest peak-to-trough decline	-98.05%	-68.48%	-29.57%
Max Drawdown (1Y) Largest decline over 1 year	-36.64%	-34.49%	-2.15%
Max Drawdown (5Y) Largest decline over 5 years	-97.82%	-68.48%	-29.34%
Max Drawdown (10Y) Largest decline over 10 years	-98.05%	—	—
Current Drawdown Current decline from peak	-88.63%	-54.01%	-34.62%
Average Drawdown Average peak-to-trough decline	-63.24%	-34.74%	-28.50%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.74%	15.95%	-1.21%

Volatility

ACRS vs. HRMY - Volatility Comparison

Aclaris Therapeutics, Inc. (ACRS) has a higher volatility of 21.82% compared to Harmony Biosciences Holdings, Inc. (HRMY) at 8.18%. This indicates that ACRS's price experiences larger fluctuations and is considered to be riskier than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ACRS	HRMY	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.82%	8.18%	+13.64%
Volatility (6M) Calculated over the trailing 6-month period	75.64%	31.02%	+44.62%
Volatility (1Y) Calculated over the trailing 1-year period	98.72%	41.98%	+56.74%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	92.46%	50.63%	+41.83%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	110.42%	52.83%	+57.59%

Financials